You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Dow
Medtronic
McKesson
Johnson and Johnson

Last Updated: February 26, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for ISV-305


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug ISV-305?

ISV-305 is an investigational drug.

There have been 15 clinical trials for ISV-305. The most recent clinical trial was a Phase 3 trial, which was initiated on December 4th 2019.

The most common disease conditions in clinical trials are Cataract, Inflammation, and Conjunctivitis. The leading clinical trial sponsors are InSite Vision, Bausch & Lomb Incorporated, and University of California, San Diego.

There are two US patents protecting this investigational drug and forty-two international patents.

Recent Clinical Trials for ISV-305
TitleSponsorPhase
Rib Fracture Analgesia Using CryoanalgesiaEpimed InternationalPhase 4
Rib Fracture Analgesia Using CryoanalgesiaUniversity of FloridaPhase 4
Rib Fracture Analgesia Using CryoanalgesiaUniversity of California, San DiegoPhase 4

See all ISV-305 clinical trials

Clinical Trial Summary for ISV-305

Top disease conditions for ISV-305
Top clinical trial sponsors for ISV-305

See all ISV-305 clinical trials

US Patents for ISV-305

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
ISV-305   Start Trial IBAT inhibitors for the treatment of liver diseases Albireo AB (Gothenburg, SE)   Start Trial
ISV-305   Start Trial Methods and compositions for producing hepatocyte-like cells The Board of Trustees of the Leland Stanford Junior University (Stanford, CA)   Start Trial
ISV-305   Start Trial Low, immune enhancing, dose mtor inhibitors and uses thereof Novartis AG (Basel, CH)   Start Trial
ISV-305   Start Trial Substituted indole Mcl-1 inhibitors Vanderbilt University (Nashville, TN)   Start Trial
ISV-305   Start Trial Salts of an epidermal growth factor receptor kinase inhibitor Celgene CAR LLC (Pembroke, BM)   Start Trial
ISV-305   Start Trial 1-(4-pyrimidinyl)-1H-pyrrolo[3,2-c]pyridine derivatives as NIK inhibitors Janssen Pharmaceutica NV (Beerse, BE)   Start Trial
ISV-305   Start Trial Pharmaceutical compounds Cascadian Therapeutics, Inc. (Seattle, WA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for ISV-305

Drugname Country Document Number Estimated Expiration Related US Patent
ISV-305 Australia 2011326871 2030-11-08   Start Trial
ISV-305 Brazil 112013010157 2030-11-08   Start Trial
ISV-305 Canada 2815749 2030-11-08   Start Trial
ISV-305 China 103260625 2030-11-08   Start Trial
ISV-305 China 105288580 2030-11-08   Start Trial
ISV-305 Cyprus 1118125 2030-11-08   Start Trial
ISV-305 Denmark 2637668 2030-11-08   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
Express Scripts
Colorcon
Dow
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.